Citizens Reiterates Market Outperform on Kura Oncology, Maintains $24 Price Target

Benzinga · 2d ago
Citizens analyst Reni J. Benjamin reiterates Kura Oncology (NASDAQ:KURA) with a Market Outperform and maintains $24 price target.